Anavex Life Sciences Corp.
ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS
Last updated:
Abstract:
The present invention provides methods for treating a genetic neurodevelopmental disorder such as Rett syndrome, comprising administering to a subject in need thereof a liquid oral dosage formulation comprising a therapeutically effective amount of ANAVEX2-73.
Status:
Application
Type:
Utility
Filling date:
22 Jul 2020
Issue date:
11 Aug 2022